Spero Therapeutics (SPRO) Reiterated at Overweight by Cantor Fitzgerald, SPR206 Results Support Further Development, Expect Upward Earnings Revisions and Multiple Expansion
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $27.0Phase 10 price target on Spero Therapeutics (NASDAQ: SPRO) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
